TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1979463
Drug: Routine maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine maintenance therapy
Study: 6311785
Drug: Ceftizoxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (1 g) administered by iv rapid injection
Study: 6311785
Drug: Ceftizoxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (1 g) administered by im injection
Study: 6311785
Drug: Probenecid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (1 g) administered one hour before ceftizoxime
Study: 31249252
Drug: dexmedetomidine 10
Normalized name: dexmedeTOMIDine 1000 MG in 250 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 10 μg/kg
Study: 31249252
Drug: dexmedetomidine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 5 μg/kg
Study: 26945402
Drug: hMG (150-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG (150-225 IU) and MPA (10 mg/d) administered simultaneously starting on cycle day 3
Study: 21094811
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) therapy for 3 months
Study: 21094811
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) therapy
Study: 16985503
Drug: Alcohol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0, 0.02-0.04 mg%, or 0.06-0.08 mg%)
Study: 1344238
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 1.5 mg/kg
Study: 1344238
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (N/S) 0.1 ml/kg (control group)
Study: 6141161
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg clorazepate
Study: 6141161
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg clorazepate
Study: 22957889
Drug: Specific oral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific oral tolerance induction (SOTI) with raw hen's egg emulsion for 6 months
Study: 12928692
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg twice daily (b.i.d.)
Study: 8848989
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg/day
Study: 8853772
Drug: Bile acids
Normalized name: Conjugated bile acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acids (ursodeoxycholic acid 500 mg and chenodeoxycholic acid 500 mg per day)
Study: 1633897
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy in pregnancy (18 patients)
Study: 1633897
Drug: Combined study
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined study groups (anticardiolipin antibody-positive vs. negative)
Study: 6385838
Drug: Furazolidone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (100 mg four times daily for 5 days)
Study: 6385838
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg four times daily for 5 days)
Study: 28566122
Drug: Standardized weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized weekly exchange of nasogastric feeding tubes
Study: 15575918
Drug: Everolimus (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (1.5 mg/day)
Study: 18089377
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) (3 g/day)
Study: 26621156
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d lisdexamfetamine dimesylate (LDX)
Study: 26621156
Drug: 70 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/d lisdexamfetamine dimesylate (LDX)
Study: 26621156
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d lisdexamfetamine dimesylate (LDX)
Study: 22964730
Drug: Peritoneal irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal irrigation with a minimum of 500 mL normal saline
Study: 14616458
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER 4 mg once daily
Study: 15948744
Drug: oxybutynin 3
Normalized name: oxyBUTYnin 3 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxybutynin 3 mg three times daily
Study: 7031516
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day bromopride for 15 days
Study: 31161388
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST-PD) for 12 weeks
Study: 24870446
Drug: Oral SGAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SGAs
Study: 18514614
Drug: Self-help cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help cognitive behavioral treatment with minimal therapist contact
Study: 17596915
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dihydrexidine
Study: 12929472
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers)
Study: 12929472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antihypertensive agents with diuretics
Study: 12929472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of angiotensin-converting enzyme inhibitor and diuretic as first-line treatment
Study: 8650997
Drug: Low‐energetic extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐energetic extracorporeal shock wave therapy (1000 impulses, energy density 0.06 mJ/mm2, administered 3 times in weekly intervals)
Study: 8650997
Drug: Low‐energetic extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐energetic extracorporeal shock wave therapy
Study: 3525431
Drug: Coenzyme A
Normalized name: Coenzyme A
DrugBank: Coenzyme A (DB01992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme A (2,000 Lipmann U daily) administered intravenously for 20 days
Study: 3525431
Drug: Sulodexide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (300 Lipasemic U daily) administered intravenously for 20 days
Study: 30204554
Drug: Active PPARγ
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PPARγ agonist pioglitazone (45 mg)
Study: 27904554
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori eradication treatment (four-drug regimen)
Study: 27904554
Drug: Placebo (capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsules and tablets)
Study: 25066248
Drug: Antepartum dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antepartum dalteparin (5000 international units once daily up to 20 weeks' gestation, and twice daily thereafter until at least 37 weeks' gestation)
Study: 18492125
Drug: Etravirine alone
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine alone (100 mg)
Study: 18492125
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg b.i.d. for 11 days) + Etravirine (100 mg on day 8)
Study: 18492125
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg q.d. for 11 days) + Etravirine (100 mg on day 8)
Study: 16825031
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (30 to 180 mg/day)
Study: 10780128
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient treatment
Study: 1442677
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg triglycyl‐lysin‐vasopressin
Study: 6363935
Drug: 4.8 million
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 million units of aqueous procaine penicillin plus 1 g of probenecid
Study: 6363935
Drug: nine tablets
Normalized name: Arginine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: nine tablets of trimethoprim‐sulfamethoxazole daily for three days
Study: 6363935
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of tetracycline four times a day for five days
Study: 16021438
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg o.d.
Study: 16021438
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg o.d.
Study: 10981241
Drug: Apothecon warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apothecon warfarin
Study: 10981241
Drug: DuPont warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuPont warfarin
Study: 10981241
Drug: Apothecon warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apothecon warfarin and DuPont warfarin
Study: 8834418
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral test dose of haloperidol (HPDL) followed by maintenance doses of 2, 5 to 8, or 10 to 15 mg twice daily for 5 days to achieve low (< 5 ng/ml), medium (10-18 ng/ml), or high (> 25 ng/ml) Css range.
Study: 8834418
Drug: C24h prediction
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: C24h prediction formula for maintenance dose of HPDL.
Study: 1600051
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate foam (Proctocort) administered rectally
Study: 4017421
Drug: Losulazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losulazine (10 to 30 mg b.i.d.)
Study: 31262343
Drug: Repetitive Sensory
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Repetitive Sensory Stimulation (RSS) for 45 minutes daily plus usual care for 2 weeks
Study: 29935486
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (800 mg every 6 hours for 24 hours)
Study: 29935486
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g every 6 hours for 24 hours)
Study: 27863809
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg LMTM twice a day
Study: 27863809
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg LMTM twice a day
Study: 27863809
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 mg LMTM twice a day)
Study: 20367560
Drug: Ordinary office-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary office-based hypertension treatment protocol (n=68)
Study: 10626559
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a dose of 3 IU/m2/day (1 mg/m2/day) (n = 35)
Study: 7651456
Drug: Tolcapone (50-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (50-800 mg)
Study: 7002480
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg tolmetin sodium daily
Study: 334478
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg indomethacin daily
Study: 29742904
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol (UP) treatment modules ordered according to pretreatment strengths
Study: 29742904
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol (UP) treatment modules ordered according to pretreatment weaknesses
Study: 26719805
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (LTOT) in COPD patients
Study: 26719805
Drug: No long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No long-term oxygen therapy (no LTOT) in COPD patients
Study: 12957222
Drug: Isradipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (10 mg)
Study: 12957222
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) + Isradipine (10 mg)
Study: 12957222
Drug: Isradipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (10 mg) + Naltrexone (50 mg)
Study: 9278834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 mg hyperbaric bupivacaine + saline)
Study: 2527542
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg once a day
Study: 921245
Drug: Ribavirin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1,000 mg/day in four divided doses)
Study: 30658942
Drug: Asymmetric split-dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric split-dose regimen (25% on the day of colonoscopy and 75% the day before)
Study: 30658942
Drug: Symmetric split-dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symmetric split-dose regimen (standard split-dose)
Study: 17299499
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.7 g long-chain n-3 fatty acids per day from week 20 for groups 1 and 2; 6.3 g from week 33 for group 3)
Study: 17299499
Drug: Control (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (olive oil capsules)
Study: 11273850
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g American ginseng
Study: 11273850
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g American ginseng
Study: 11273850
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g American ginseng
Study: 11273850
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng administered 40 min before glucose challenge
Study: 9340441
Drug: Nebulizer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer therapy (0.5 ml ‐ 125 micrograms ipratropium bromide and 250 micrograms phenoterol)
Study: 9340441
Drug: Aerosol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol therapy (40 micrograms ipratropium and 100 micrograms phenoterol)
Study: 1285936
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitrendipine twice daily (titrated up to 30 mg twice daily during open label period)
Study: 3809304
Drug: Clomipramin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramin, 50 mg (oral)
Study: 3809304
Drug: Amitriptylin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptylin, 50 mg (oral)
Study: 3809304
Drug: Desipramin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramin, 50 mg (oral)
Study: 3809304
Drug: Imipramin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramin, 50 mg (oral)
Study: 3809304
Drug: Diazepam, 10
Normalized name: DiazePAM, 10 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam, 10 mg (oral)
Study: 3809304
Drug: Carbamazepin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepin, 200 mg (oral)
Study: 3809304
Drug: Haloperidol, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, 3 mg (oral)
Study: 3809304
Drug: Clomipramin, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramin, 25 mg (intravenous)
Study: 21793769
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose oxytocin
Study: 21793769
Drug: Standard incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard incremental low-dose oxytocin
Study: 17021740
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% plus 50 mg magnesium
Study: 11913290
Drug: 6.5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5% hydrogen peroxide strip system, used twice daily for 30 minutes (total of 56 contact hours over 8 weeks)
Study: 9707740
Drug: Omeprazole; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole; specific dosage and duration not mentioned.
Study: 17068314
Drug: Placebo; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; specific dosage and duration not mentioned.
Study: 8551804
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with < or = 5% residual blasts at D15
Study: 8551804
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with > 5% residual blasts at D15
Study: 2246174
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation tests in normal subjects
Study: 2246174
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation tests in asthmatic subjects
Study: 2246174
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg/day) and flurbiprofen (150 mg/day) pretreatment in normal subjects
Study: 6936982
Drug: treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with a mixture of 7 grass pollen extracts (Allpyral)
Study: 6936982
Drug: treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with a cocksfoot pollen extract (Allpyral)
Study: 6936982
Drug: treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with a rye pollen extract (Allpyral)
Study: 6936982
Drug: treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with a mixture containing 50% rye pollen and 50% cocksfoot (Allpyral)
Study: 6936982
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group without immunotherapy
Study: 24020078
Drug: nCPAP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP combined with antireflux medicine (esomeprazole 40 mg/d and mosapride citrate 5 mg, 3 times a day, oral)
Study: 24020078
Drug: nCPAP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP combined with antireflux medicine
Study: 19645974
Drug: 0.25% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% levobupivacaine or bupivacaine (Treatment Group)
Study: 17302060
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) - glucosidorum tripterygll totorum and Yishen Juanbi Pill
Study: 17302060
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (WM) - non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs
Study: 15217308
Drug: Fluvastatin (Lescol)
Normalized name: fluvastatin Oral Capsule [Lescol]
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (Lescol) 40 mg twice daily plus dietary counselling
Study: 11216808
Drug: Azathioprine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (4 mg/kg intraoperatively and 2.0 +/- 0.5 mg/kg once daily for 3 months)
Study: 9773716
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) at 0.625 mg/day
Study: 9773716
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) at 2.5 mg daily (continuous MPA)
Study: 9773716
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) at 10 mg on days 1-12 (cyclical MPA)
Study: 9773716
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (MP) at 200 mg on days 1-12 (cyclical)
Study: 9495426
Drug: Tropisetron 2
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 2 mg
Study: 7848884
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg (rescue infusion)
Study: 7848884
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg, 10 mg, 20 mg, 40 mg (study I)
Study: 3141867
Drug: Active allergen
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active allergen injection during treatment sessions
Study: 3141867
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection during treatment sessions
Study: 3141867
Drug: Neutralization subcutaneous
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralization subcutaneous treatment
Study: 28918441
Drug: LSD (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (200 μg)
Study: 27624148
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of oral THC twice daily